Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
Closed Posted
- Opportunity number
- RFA-CA-25-006
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Up to $150,000
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Categories
-
- Education
- Health
- Eligible applicants
-
- Tribal Organizations (Not Federally Recognized)
- State Governments
- Independent School Districts
- Small Businesses
- County Governments
- Higher Education Inst. (Public)
- Tribal Governments (Federally Recognized)
- Non-501(c)(3) Nonprofits
- City/Township Governments
- Public or Indian Housing Auth.
- Higher Education Inst. (Private)
- For Profit Organizations
- 501(c)(3) Nonprofits
- Special District Governments
- Other
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Cancer Institute (NCI) is seeking revision applications from currently funded U01 research projects to incorporate innovative technologies developed through the Innovative Molecular Analysis Technologies (IMAT) program. The Department of Health and Human Services National Institutes of Health aims to accelerate cancer research by promoting interdisciplinary collaboration and independent validation of emerging scientific technologies. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, for-profit organizations, small businesses, tribal organizations, and various government entities. Applicants must propose to expand upon their original research questions or accelerate progress by integrating new technical approaches or devices developed through NCI support. The key evaluation criteria will focus on scientific merit, program relevance, and the potential to advance cancer research methodologies. The funding opportunity (RFA-CA-25-006) has a proposal due date of December 9, 2025, under the Cancer Detection and Diagnosis Research program.
The funding will be provided through a cooperative agreement mechanism (U01) with optional clinical trials, and while specific award amounts are not explicitly detailed, the Cancer Detection and Diagnosis Research program typically awards grants ranging from $200,000 to nearly $3 million. Project periods are generally expected to span 2-5 years, with research to be conducted at the recipient organizations' facilities across the United States. The primary goal is to support translational research that can potentially improve cancer detection, diagnosis, and patient outcomes by developing and validating innovative molecular analysis technologies. Funded projects will be expected to demonstrate clear potential for advancing scientific understanding and developing novel tools for cancer research.
Synopsis
2 versions
Update #2 · Latest ·
The purpose of this Notice of Funding Opportunity (NOFO) is to encourage revision applications from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or device developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this NOFO are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.As a component of the NCI IMAT program, this NOFO aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.
Update #1 ·
The purpose of this Notice of Funding Opportunity (NOFO) is to encourage revision applications from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or device developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this NOFO are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this NOFO aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.
Files
| File | Type | Posted |
|---|---|---|
| RFA-CA-25-006-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity